875548-97-3

Usage

Uses

Used in Organic Chemistry:
4'-Fluoro-2'-methoxy-5'-isopropyl-4-trifluoromethyl-1,1'-biphenyl-2-methanol is used as a building block in organic chemistry for the synthesis of various complex molecules. Its unique structural features make it a valuable component in the creation of new organic compounds with specific properties.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4'-Fluoro-2'-methoxy-5'-isopropyl-4-trifluoromethyl-1,1'-biphenyl-2-methanol is used as a key intermediate in the development of novel drug molecules. The presence of fluorine and trifluoromethyl groups is particularly advantageous, as these elements can improve the pharmacological properties of drugs, including their bioavailability and metabolic stability.
Used in Medicinal Chemistry Synthesis:
4'-Fluoro-2'-methoxy-5'-isopropyl-4-trifluoromethyl-1,1'-biphenyl-2-methanol serves as an important candidate for medicinal chemistry synthesis. Its unique combination of functional groups allows for the design and synthesis of drug molecules with enhanced therapeutic effects and improved pharmacokinetic profiles.
Further research and studies on 4'-Fluoro-2'-methoxy-5'-isopropyl-4-trifluoromethyl-1,1'-biphenyl-2-methanol are essential to fully explore its potential applications and to develop new methodologies for its synthesis and utilization in various fields.

Upstream product

• 875446-29-0 [4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]boronic acid 
• 64372-62-9 (2-chloro-5-(trifluoromethyl)phenyl)methanol 
• 702641-05-2 [2-iodo-5-(trifluoromethyl)phenyl]methanol 
• 702641-06-3 2-(bromomethyl)-1-iodo-4-(trifluoromethyl)benzene 
• 851513-74-1 2-(3-(trifluoromethyl)phenyl)-4,5-dihydrooxazole 
• 914221-54-8 1-(5-bromo-2-fluoro-4-methoxyphenyl)ethan-1-one 
• 958029-46-4 2-(5-bromo-2-fluoro-4-methoxyphenyl)propan-2-ol 
• 944317-92-4 1-bromo-4-fluoro-2-methoxy-5-(propan-2-yl)-benzene 
• 958029-47-5 2-[4'-fluoro-2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-yl]-4,5-dihydro-1,3-oxazole 
• 348-57-2 2,4-difluorobromobenzene 
• 368-77-4 3-trifluoromethylbenzonitrile 
• 450-88-4 1-bromo-4-fluoro-2-methoxybenzene 
• 868166-20-5 2-iodo-5-(trifluoromethyl)benzonitrile 
• 875446-55-2 2-fluoro-4-methoxy-1-(prop-1-en-2-yl)benzene 

Downstream Products

• 875551-28-3 2'-(chloromethyl)-4-fluoro-5-isopropyl-2-methoxy-4'-(trifluoromethyl)biphenyl 
• 875549-49-8 (+)-(5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-yl]methyl}-4,4-dimethyl-1,3-oxazolidin-2-one 
• 1312671-81-0 (-)-(5S)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-yl]methyl}-4,4-dimethyl-1,3-oxazolidin-2-one 
• 1312671-76-3 (+)-(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-yl]methyl}-4,5-dimethyl-1,3-oxazolidin-2-one 
• 1312671-75-2 5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-yl]methyl}-4,4-dimethyl-1,3-oxazolidin-2-one 
• 875446-37-0 anacetrapib 
• 1620289-77-1 (1R,2S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-[(E)-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methylidene)amino]propan-1-ol 
• 1220703-07-0 (1R,2S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-[({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)amino]propan-1-ol 
• 875548-98-4 2'-(bromomethyl)-4-fluoro-2-methoxy-5-(propan-2-yl)-4'-(trifluoromethyl)biphenyl 

Relevant academic research and scientific papers

Pd-Catalysed direct C(sp2)-H fluorination of aromatic ketones: Concise access to anacetrapib

The Pd-cataylsed direct ortho-C(sp2)-H fluorination of aromatic ketones has been developed for the first time. The reaction features good regioselectivity and simple operations, constituting an alternative shortcut to access fluorinated ketones. A concise synthesis of anacetrapib has also been achieved by using late-stage C-H fluorination as a key step.

Anacetrapib key intermediate as well as synthesis method and application thereof

The invention provides a synthesis method of an Anacetrapib key intermediate (a compound shown in a formula H). According to the method, all starting raw materials are simple and easy to obtain, and synthesis steps can be shortened. The method is short in route; initial raw materials are easy to obtain, and the overall reaction yield is high; and the reaction route is simple in post-treatment and few in reaction by-products.

Preparation method of Anacetrapib

The invention relates to a preparation method of a compound represented by the formula (I). The preparation method comprises the following steps: (1) reacting 2-chloro-5-trifluoromethyl-aniline (II) with (4-fluoro-5-isopropyl-2-methoxyphenyl)boric acid (III) to obtain 2-(4-fluoro-5-isopropyl-20methoxyphenyl)-5-trifluoromethyl-aniline (formula IV); (2) reacting the compound (formula IV) with tert-butyl nitrite, acetaldehyde, and alkalis to obtain 2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-trifluoromethyl-benzyl alcohol (formula V); (3) reacting the compound (formula V) with a halogenation reagent, and then adding (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-1,3-oxazolidine-2-one (VI) into the reaction mixture to carry out reactions so as to obtain (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4'-fluoro-5'-isoproypyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl}-4-methyl-1,3-oxazolidine-2-one represented by the formula (I), namely Anacetrapib.

Process for a CETP Inhibitor

An efficient process is disclosed for producing the compound of formula I, which is the CETP inhibitor anacetrapib, which raises HDL-cholesterol and reduces LDL-cholesterol in human patients and may be effective for treating or reducing the risk of developing atherosclerosis:

PROCESS FOR PREPARATION OF ANACETRAPIB AND INTERMEDIATES THEREOF

The present invention relates to a novel process for the preparation of anacetrapib. The present invention also relates to novel intermediate or its salt and its use in the preparation of anacetrapib.

SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF

The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof.

PROCESS FOR A CETP INHIBITOR

An efficient process is disclosed for producing the compound of formula I, which is the CETP inhibitor anacetrapib, which raises HDL-cholesterol and reduces LDL-cholesterol in human patients and may be effective for treating or reducing the risk of developing atherosclerosis:.

COMPOUNDS FOR INCREASE OF HDL-C LEVEL AND USES THEREOF

Compounds for inhibiting cholesterol ester transport protein (CETP) activity and application thereof. These compounds include compounds of formula (I), and the pharmaceutically acceptable salts, solvates, non-covalent complexes,chelates, or prodrugs there

Synthesis of intermediates for preparing anacetrapib and derivates thereof

The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof.

Synthesis of intermediates for preparing anacetrapib and derivates thereof

The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof.